streptomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 2481 57-92-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • streptomycin
  • streptomycin sulfate
An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis.
  • Molecular weight: 581.58
  • Formula: C21H39N7O12
  • CLOGP: -3.46
  • LIPINSKI: 3
  • HAC: 19
  • HDO: 14
  • TPSA: 331.43
  • ALOGS: -1.66
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 55 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 34.39 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.34 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.78 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.65 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.30 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1,ZAP70 25
kinase-selectivity-class CHUK,MAP2K6,PDK1 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Feb. 18, 1946 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaginal flatulence 76.77 50.43 20 1135 12618 90614674
Proctitis 73.03 50.43 20 1135 15239 90612053
Drug reaction with eosinophilia and systemic symptoms 71.46 50.43 25 1130 42733 90584559
Female genital tract fistula 69.91 50.43 20 1135 17848 90609444
Radiculopathy 69.21 50.43 20 1135 18485 90608807
Vaginal discharge 68.22 50.43 20 1135 19444 90607848
Chronic sinusitis 64.25 50.43 20 1135 23782 90603510
Oral candidiasis 60.25 50.43 21 1134 35434 90591858
Paraesthesia oral 58.64 50.43 20 1135 31639 90595653
Macular degeneration 55.08 50.43 20 1135 37950 90589342
Paradoxical drug reaction 54.43 50.43 13 1142 5753 90621539

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 128.98 44.87 29 1114 4709 42615483
Drug resistance 124.09 44.87 43 1100 34205 42585987
Tuberculoma of central nervous system 77.07 44.87 12 1131 257 42619935
Immune reconstitution inflammatory syndrome 75.13 44.87 22 1121 10121 42610071
Pathogen resistance 68.23 44.87 21 1122 11429 42608763
Immune reconstitution inflammatory syndrome associated tuberculosis 67.84 44.87 12 1131 569 42619623
Urinary tract inflammation 63.21 44.87 10 1133 238 42619954
Hepatitis cholestatic 62.71 44.87 19 1124 9805 42610387
Conductive deafness 49.33 44.87 9 1134 508 42619684

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 177.43 43.98 41 2233 9776 110577249
Drug resistance 147.52 43.98 52 2222 56322 110530703
Immune reconstitution inflammatory syndrome associated tuberculosis 89.75 43.98 16 2258 1038 110585987
Pathogen resistance 85.54 43.98 26 2248 17646 110569379
Tuberculoma of central nervous system 84.14 43.98 14 2260 603 110586422
Immune reconstitution inflammatory syndrome 79.08 43.98 24 2250 16202 110570823
Drug reaction with eosinophilia and systemic symptoms 73.05 43.98 35 2239 82060 110504965
Vaginal flatulence 68.00 43.98 20 2254 12124 110574901
Female genital tract fistula 61.94 43.98 20 2254 16499 110570526
Proctitis 61.46 43.98 20 2254 16907 110570118
Urinary tract inflammation 61.11 43.98 10 2264 388 110586637
Vaginal discharge 60.35 43.98 20 2254 17888 110569137
Radiculopathy 58.84 43.98 20 2254 19316 110567709
Macular degeneration 56.62 43.98 20 2254 21639 110565386
Conductive deafness 56.36 43.98 9 2265 299 110586726
Chronic sinusitis 53.76 43.98 20 2254 25064 110561961
Drug-induced liver injury 52.65 43.98 32 2242 120035 110466990
Oral candidiasis 48.85 43.98 22 2252 44738 110542287
Paraesthesia oral 48.04 43.98 20 2254 33651 110553374
Pyrexia 46.46 43.98 73 2201 898192 109688833
Hepatitis cholestatic 45.07 43.98 16 2258 17550 110569475

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07AA04 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
ATC A07AA54 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
ATC J01GA01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
AMINOGLYCOSIDE ANTIBACTERIALS
Streptomycins
ATC J04AM01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
FDA CS M0000946 Aminoglycosides
FDA EPC N0000175477 Aminoglycoside Antibacterial
FDA EPC N0000175483 Antimycobacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:36043 antimicrobial drug
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:48001 protein synthesis inhibitor
CHEBI has role CHEBI:76969 bacterial metabolite
CHEBI has role CHEBI:86328 antifungal agrochemical

Related Drugs by ATC class:

A07AA Antibiotics 12 drugs
amphotericin BcolistinfidaxomicinkanamycinnatamycinneomycinnystatinparomomycinPolymyxin Brifamycinrifaximinvancomycin
J01GA Streptomycins 1 drug
streptoduocin
J04AM Combinations of drugs for treatment of tuberculosis 11 drugs
ethambutolisoniazidlevofloxacinlomefloxacinprotionamidepyrazinamiderifabutinrifampicinsulfamethoxazolethioacetazonetrimethoprim

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tularemia indication 19265001
Acute tuberculosis indication 25629007
Granuloma inguinale indication 28867007 DOID:9113
Plague indication 58750007 DOID:3482
Klebsiella cystitis indication 60867007
Haemophilus influenzae pneumonia indication 70036007
Brucellosis indication 75702008 DOID:11077
Pulmonary tuberculosis indication 154283005 DOID:2957
Chancroid indication 266143009 DOID:13778
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Bacterial urinary infection indication 312124009
Aerobic Gram-Negative Bacteremia indication
Synergy for Streptococcal Endocarditis indication
Haemophilus Endocarditis indication
Synergy for Enterococcal Endocarditis indication
Enterococcus Urinary Tract Infection indication
Synergy for Enterococcal Infections indication
H. Influenzae Meningitis indication
Pulmonary Mycobacterium avium complex infection off-label use 186342000
Hypocalcemia contraindication 5291005
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Tinnitus contraindication 60862001
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Pregnancy, function contraindication 289908002
Vertigo contraindication 399153001
Inner Ear Disturbance contraindication
Disorder of the 8th Cranial Nerve contraindication
Infant Botulism contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle Bacterial enteritis caused by Escherichia coli Indication
Cattle Bacterial enteritis caused by Salmonella spp Indication
Chickens Nonspecific infectious enteritis caused by bacteria Indication
Swine Bacterial enteritis caused by Escherichia coli Indication
Swine Bacterial enteritis caused by Salmonella spp Indication

🐶 Veterinary products

ProductApplicantIngredients
Entromycin Powder Zoetis Inc. 2
STREP SOL Huvepharma EOOD 1
Streptomycin Oral Solution Huvepharma EOOD 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.43 acidic
pKa2 12.62 acidic
pKa3 13.36 acidic
pKa4 13.79 acidic
pKa5 11.91 Basic
pKa6 11.21 Basic
pKa7 6.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
30S ribosomal protein S12 Ribosomal protein WOMBAT-PK

External reference:

IDSource
4019933 VUID
N0000148018 NUI
D01350 KEGG_DRUG
3810-74-0 SECONDARY_CAS_RN
4017475 VANDF
4019933 VANDF
C0038425 UMLSCUI
CHEBI:17076 CHEBI
SRY PDB_CHEM_ID
CHEMBL372795 ChEMBL_ID
CHEMBL3184791 ChEMBL_ID
D013307 MESH_DESCRIPTOR_UI
DB01082 DRUGBANK_ID
10923 IUPHAR_LIGAND_ID
3685 INN_ID
Y45QSO73OB UNII
19649 PUBCHEM_CID
10109 RXNORM
1794 MMSL
5514 MMSL
d00159 MMSL
002770 NDDF
004895 NDDF
387223008 SNOMEDCT_US
40877002 SNOMEDCT_US
73246001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Streptomycin HUMAN PRESCRIPTION DRUG LABEL 1 39822-0706 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 19 sections